Wednesday, July 4, 2018

ZURICH (Reuters) - Swiss drugmaker Roche said on Monday that a trial showed its immunotherapy Tecentriq plus the chemotherapy Abraxane significantly reduced the risk of disease worsening or death in people with metastatic triple negative breast cancer.


from Reuters: Health News https://ift.tt/2lRTM6V

Related Posts:

  • LATEST HEALTH NEWSU.S. health regulators said on Friday a third cancer-causing toxin was found in some blood pressure pills recalled by India's Hetero Labs Ltd a day earlier, adding to a global recall of commonly used drugs to treat hypertensi… Read More
  • LATEST HEALTH NEWS(Reuters Health) - Three in four obese people with diabetes who had a common type of weight-loss operation called Roux-en-Y gastric bypass (RYGB) experienced remission of their diabetes within a year after surgery, a Danish s… Read More
  • LATEST HEALTH NEWSAn Ebola treatment center at the epicenter of the current outbreak in eastern Democratic Republic of Congo has resumed operations after it was closed in response to an attack last week, the Congolese health ministry said on S… Read More
  • LATEST HEALTH NEWSThe Court of Appeal of Quebec upheld on Friday the bulk of a 2015 decision that awarded around C$15 billion ($11.29 billion)to smokers in the Canadian province, dealing a blow to Big Tobacco. from Reuters: Health News ht… Read More
  • LATEST HEALTH NEWS(Reuters Health) - When multiple doctors are on the job, there's a higher likelihood that a correct diagnosis will be made, a new study suggests. from Reuters: Health News https://ift.tt/2tMjP3c … Read More

0 comments:

Post a Comment

Followers

Contact Form

Name

Email *

Message *

Popular Posts

FOLLOW BY EMAIL

Enter your email address:

Delivered by FeedBurner